We appreciate the opportunity to discuss the characteristics of paraneoplastic pemphigus (PNP), further than was possible in our original Primer (Pemphigus. Nat. Rev 2 , which proposes classifying PNP as a pemphiguslike subtype of paraneoplastic autoimmune multi-organ syndrome (PAMS).
We agree that the PAMS terminology is more inclusive of the heterogeneous clinical presentation and pathophysiology of this disease than the term PNP, particularly in relation to the T cell-mediated cytotoxic effects associated with lichenoid tissue reactions, the extension of the humoral response to nondesmoglein autoantigens and the involvement of organs other than the skin. In the Primer, we use the term PNP to refer to the entire disease spectrum, whereas Amber proposes that the term PAMS, previously coined by Grando and colleagues 3 , is more appropriate. Both the Primer and the Correspondence highlight the aspects of PNP presentation, pathophysiology and prognosis that differ from classic pemphigus, including severe erosive stomatitis, bronchiolitis obliterans and high mortality. Thus, it is important that the lichenoid variant of PNP is recognized as a paraneoplastic process, so that underlying conditions and potential complications can be diagnosed and managed.
However, we disagree with the statement that PNP "is an unrelated condition" to pemphigus. Several studies have identified shared histological features and pathophysiological mechanisms of the bullous lesions in PNP and pemphigus vulgaris (PV): the skin blisters in PNP show suprabasal acantholysis characteristic of blisters observed in patients with PV, passive transfer of anti-desmoglein 3 antibodies isolated from patients with PNP to neonatal mice causes blisters that are histologically identical to those in patients with PV 4 and anti-desmoglein 3 V H gene usage in one patient with PNP matched the immunodominant gene usage reported in patients with PV 5, 6 . Thus, PNP and PV demonstrate common histological, pathophysiological and immunogenetic disease mechanisms.
The major limitation of our current knowledge of PNP is that we have not yet identified the scope of autoantigens recognized by T cells in the autoimmune cellular responses that lead to lichenoid tissue reactions. Once the autoimmune targets of those T cells are identified, we should have a better understanding of the pathophysiology of PNP in the skin and other organs. Of note, desmoglein 3-reactive T cells induce lichenoid tissue reactions in the skin as well as in the lung in mice, suggesting that PNP could be linked to PV through this shared target antigen both in cellular and humoral autoimmune reactions 7, 8 . We propose that either term, PNP or PAMS, would be appropriate to describe this disease, and that it should be acknowledged that the term PNP is more precisely used to describe disease presentations that incorporate pemphigus-like bullous lesions, whereas PAMS is more inclusive to describe all disease presentations.
